Leukemia and Lymphoma Society

  B Cell Lymphoma Prognosis is related to the information here. The sure means of  ensuring accurate diagnosis by pathologists  is to analyze the lymphoma  from several different angles. Unlike most non-Hodgkin's lymphomas (which are generally B-cell related), CTCL is caused by a mutation of T cells. The morphological characteristics of the lymph nodes and tissues provide doctors with valuable data on the disease, helping them distinguish benign forms of lymphoma from the malignant ones. This is why it is very important that you go to a doctor whose lab is well equipped. According to oncologists, patients who suffer from aggressively progressing Non-Hodgkin's Lymphoma ... Read Full Story

Miv Investments Inc. has initiated an independent bullish technical trading alert for 11/23/09 on CytRx Corporation (NASDAQ:CYTR). Shares of the company finished trading during 11/20/09 at $1.14 per share, up 20.18% from the opening bell on heavy buying pressure. As of 11/18/09, the biopharmaceutical company announced plans to initiate an open-label, multinational Phase 2 clinical trial with its doxorubicin prodrug INNO-206 as a second-line treatment in patients with advanced gastric (stomach) cancer. CytRx President and CEO Steven A. Kriegsman said, “This planned clinical trial is a key step forward in our plans to build a commercial oncology franchise for CytRx. We have studied the ... Read Full Story

  Bbs Leukemia Lymphoma Society is related to the information here. Cutaneous T cell lymphoma (CTCL) is  one  of non-Hodgkin's lymphoma, which is basically a cancer of the immune system. T-cell lymphoma usually start on the trunk but if treatment is not soon, it could  also spread to other parts of your body presenting as  deep, red  plaques. The morphological characteristics of the lymph nodes and tissues provide doctors with valuable data on the disease, helping them distinguish benign forms of lymphoma from the malignant ones. This is why it is very important that you go to a doctor whose lab is well equipped. ... Read Full Story

Miv Investments Inc. has initiated an independent bullish technical trading alert for 11/23/09 on CytRx Corporation (NASDAQ:CYTR). Shares of the company finished trading during 11/20/09 at $1.14 per share, up 20.18% from the opening bell on heavy buying pressure. As of 11/18/09, the biopharmaceutical company announced plans to initiate an open-label, multinational Phase 2 clinical trial with its doxorubicin prodrug INNO-206 as a second-line treatment in patients with advanced gastric (stomach) cancer. CytRx President and CEO Steven A. Kriegsman said, “This planned clinical trial is a key step forward in our plans to build a commercial oncology franchise for CytRx. We have studied the ... Read Full Story

  B-Cell Lymphoma 4Th Line Treatment is related to the information here. There are several types of lymphoma, for instance the t-cell lymphoma, which first affects the skin and then spreads to rest of the body. The symptom of Cutaneous t-cell lymphoma is  itching that results  dark patches on the skin  following scratches -  the disease progressively transforms into mushroom shaped tumors in the long run. Lymphoma can manifest in different forms through symptoms that are associated with other ailments necessitating the need to use different types of techiques for its diagnosis. Today, AIDS-related lymphoma is generally diagnosed  quite late, after the disease has ... Read Full Story